Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

Previous studies have shown sex‐related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex‐related differences in the safety of S‐1 plus oxaliplatin (SOX) and S‐1 plus cisplatin (CS) in 663 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yasuhide, Koizumi, Wasaburo, Nishikawa, Kazuhiro, Gotoh, Masahiro, Fuse, Nozomu, Sugimoto, Naotoshi, Nishina, Tomohiro, Amagai, Kenji, Chin, Keisho, Niwa, Yasumasa, Tsuji, Akihito, Imamura, Hiroshi, Tsuda, Masahiro, Yasui, Hirofumi, Fujii, Hirofumi, Yamaguchi, Kensei, Yasui, Hisateru, Hironaka, Shuichi, Shimada, Ken, Hyodo, Ichinosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726691/
https://www.ncbi.nlm.nih.gov/pubmed/31254422
http://dx.doi.org/10.1111/cas.14117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726691/
https://www.ncbi.nlm.nih.gov/pubmed/31254422
http://dx.doi.org/10.1111/cas.14117

Ejemplares similares